1209 related articles for article (PubMed ID: 26515462)
1. Etoposide enhances antitumor efficacy of MDR1-driven oncolytic adenovirus through autoupregulation of the MDR1 promoter activity.
Su BH; Shieh GS; Tseng YL; Shiau AL; Wu CL
Oncotarget; 2015 Nov; 6(35):38308-26. PubMed ID: 26515462
[TBL] [Abstract][Full Text] [Related]
2. Inhibition of the multidrug-resistant phenotype by targeting YB-1 with a conditionally oncolytic adenovirus: implications for combinatorial treatment regimen with chemotherapeutic agents.
Mantwill K; Köhler-Vargas N; Bernshausen A; Bieler A; Lage H; Kaszubiak A; Surowiak P; Dravits T; Treiber U; Hartung R; Gansbacher B; Holm PS
Cancer Res; 2006 Jul; 66(14):7195-202. PubMed ID: 16849566
[TBL] [Abstract][Full Text] [Related]
3. Combination of oncolytic adenovirus and endostatin inhibits human retinoblastoma in an in vivo mouse model.
Wang H; Wei F; Li H; Ji X; Li S; Chen X
Int J Mol Med; 2013 Feb; 31(2):377-85. PubMed ID: 23229955
[TBL] [Abstract][Full Text] [Related]
4. A survivin-mediated oncolytic adenovirus induces non-apoptotic cell death in lung cancer cells and shows antitumoral potential in vivo.
Li B; Liu X; Fan J; Qi R; Bo L; Gu J; Qian Q; Qian C; Liu X
J Gene Med; 2006 Oct; 8(10):1232-42. PubMed ID: 16900558
[TBL] [Abstract][Full Text] [Related]
5. An oncolytic adenovirus selective for retinoblastoma tumor suppressor protein pathway-defective tumors: dependence on E1A, the E2F-1 promoter, and viral replication for selectivity and efficacy.
Jakubczak JL; Ryan P; Gorziglia M; Clarke L; Hawkins LK; Hay C; Huang Y; Kaloss M; Marinov A; Phipps S; Pinkstaff A; Shirley P; Skripchenko Y; Stewart D; Forry-Schaudies S; Hallenbeck PL
Cancer Res; 2003 Apr; 63(7):1490-9. PubMed ID: 12670895
[TBL] [Abstract][Full Text] [Related]
6. Dual E1A oncolytic adenovirus: targeting tumor heterogeneity with two independent cancer-specific promoter elements, DF3/MUC1 and hTERT.
Doloff JC; Jounaidi Y; Waxman DJ
Cancer Gene Ther; 2011 Mar; 18(3):153-66. PubMed ID: 20865021
[TBL] [Abstract][Full Text] [Related]
7. A modified E2F-1 promoter improves the efficacy to toxicity ratio of oncolytic adenoviruses.
Rojas JJ; Cascallo M; Guedan S; Gros A; Martinez-Quintanilla J; Hemminki A; Alemany R
Gene Ther; 2009 Dec; 16(12):1441-51. PubMed ID: 19710704
[TBL] [Abstract][Full Text] [Related]
8. ICOVIR-5 shows E2F1 addiction and potent antiglioma effect in vivo.
Alonso MM; Cascallo M; Gomez-Manzano C; Jiang H; Bekele BN; Perez-Gimenez A; Lang FF; Piao Y; Alemany R; Fueyo J
Cancer Res; 2007 Sep; 67(17):8255-63. PubMed ID: 17804740
[TBL] [Abstract][Full Text] [Related]
9. A novel apoptotic mechanism of genetically engineered adenovirus-mediated tumour-specific p53 overexpression through E1A-dependent p21 and MDM2 suppression.
Yamasaki Y; Tazawa H; Hashimoto Y; Kojima T; Kuroda S; Yano S; Yoshida R; Uno F; Mizuguchi H; Ohtsuru A; Urata Y; Kagawa S; Fujiwara T
Eur J Cancer; 2012 Sep; 48(14):2282-91. PubMed ID: 22244827
[TBL] [Abstract][Full Text] [Related]
10. HCCS1-armed, quadruple-regulated oncolytic adenovirus specific for liver cancer as a cancer targeting gene-viro-therapy strategy.
Xu HN; Huang WD; Cai Y; Ding M; Gu JF; Wei N; Sun LY; Cao X; Li HG; Zhang KJ; Liu XR; Liu XY
Mol Cancer; 2011 Nov; 10():133. PubMed ID: 22040050
[TBL] [Abstract][Full Text] [Related]
11. Treatment of chemotherapy resistant ovarian cancer with a MDR1 targeted oncolytic adenovirus.
Rein DT; Volkmer A; Beyer IM; Curiel DT; Janni W; Dragoi A; Hess AP; Maass N; Baldus SE; Bauerschmitz G; Breidenbach M
Gynecol Oncol; 2011 Oct; 123(1):138-46. PubMed ID: 21741695
[TBL] [Abstract][Full Text] [Related]
12. Transthyretin-driven oncolytic adenovirus suppresses tumor growth in orthotopic and ascites models of hepatocellular carcinoma.
Hsieh JL; Lee CH; Teo ML; Lin YJ; Huang YS; Wu CL; Shiau AL
Cancer Sci; 2009 Mar; 100(3):537-45. PubMed ID: 19134007
[TBL] [Abstract][Full Text] [Related]
13. An E2F-responsive replication-selective adenovirus targeted to the defective cell cycle in cancer cells: potent antitumoral efficacy but no toxicity to normal cell.
Tsukuda K; Wiewrodt R; Molnar-Kimber K; Jovanovic VP; Amin KM
Cancer Res; 2002 Jun; 62(12):3438-47. PubMed ID: 12067986
[TBL] [Abstract][Full Text] [Related]
14. Increased safety with preserved antitumoral efficacy on hepatocellular carcinoma with dual-regulated oncolytic adenovirus.
Zhang Q; Chen G; Peng L; Wang X; Yang Y; Liu C; Shi W; Su C; Wu H; Liu X; Wu M; Qian Q
Clin Cancer Res; 2006 Nov; 12(21):6523-31. PubMed ID: 17085667
[TBL] [Abstract][Full Text] [Related]
15. A novel oncolytic adenovirus expressing Escherichia coli cytosine deaminase exhibits potent antitumor effect on human solid tumors.
Zhang J; Wei F; Wang H; Li H; Qiu W; Ren P; Chen X; Huang Q
Cancer Biother Radiopharm; 2010 Aug; 25(4):487-95. PubMed ID: 20735209
[TBL] [Abstract][Full Text] [Related]
16. Killing effect of TNF-mediated by conditionally replicating adenovirus on esophageal cancer and lung cancer cell lines.
Jiang YQ; Zhang Z; Cai HR; Zhou H
Int J Clin Exp Pathol; 2015; 8(11):13785-94. PubMed ID: 26823692
[TBL] [Abstract][Full Text] [Related]
17. Biodistribution and safety assessment of bladder cancer specific recombinant oncolytic adenovirus in subcutaneous xenografts tumor model in nude mice.
Wang F; Wang Z; Tian H; Qi M; Zhai Z; Li S; Li R; Zhang H; Wang W; Fu S; Lu J; Rodriguez R; Guo Y; Zhou L
Curr Gene Ther; 2012 Apr; 12(2):67-76. PubMed ID: 22384806
[TBL] [Abstract][Full Text] [Related]
18. E1A, E1B double-restricted adenovirus with RGD-fiber modification exhibits enhanced oncolysis for CAR-deficient biliary cancers.
Wakayama M; Abei M; Kawashima R; Seo E; Fukuda K; Ugai H; Murata T; Tanaka N; Hyodo I; Hamada H; Yokoyama KK
Clin Cancer Res; 2007 May; 13(10):3043-50. PubMed ID: 17505007
[TBL] [Abstract][Full Text] [Related]
19. Systemic toxicity-efficacy profile of ICOVIR-5, a potent and selective oncolytic adenovirus based on the pRB pathway.
Cascallo M; Alonso MM; Rojas JJ; Perez-Gimenez A; Fueyo J; Alemany R
Mol Ther; 2007 Sep; 15(9):1607-15. PubMed ID: 17579575
[TBL] [Abstract][Full Text] [Related]
20. pH-sensitive oncolytic adenovirus hybrid targeting acidic tumor microenvironment and angiogenesis.
Choi JW; Jung SJ; Kasala D; Hwang JK; Hu J; Bae YH; Yun CO
J Control Release; 2015 May; 205():134-43. PubMed ID: 25575865
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
